# Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

> **NCT06751524** · — · AVAILABLE · sponsor: **Agenus Inc.**

## Conditions studied

- Colorectal Cancer (CRC)
- Pancreatic Cancer
- Non-Small Cell Lung Cancer (NSCLC)
- Hepatocellular Carcinoma (HCC)
- Melanoma
- Sarcoma
- Ovarian Cancer
- Prostate Cancer

## Interventions

- **DRUG:** Botensilimab
- **DRUG:** Balstililmab

## Key facts

- **NCT ID:** NCT06751524
- **Lead sponsor:** Agenus Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06751524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06751524, "Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT06751524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*